<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534"><gtr:id>E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534</gtr:id><gtr:name>Spanish National Research Council (CSIC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DEB2C117-3BE0-43B6-8B6F-0D81B153C1BB"><gtr:id>DEB2C117-3BE0-43B6-8B6F-0D81B153C1BB</gtr:id><gtr:name>European Hopital Georges Pompidou</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534"><gtr:id>E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534</gtr:id><gtr:name>Spanish National Research Council (CSIC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DEB2C117-3BE0-43B6-8B6F-0D81B153C1BB"><gtr:id>DEB2C117-3BE0-43B6-8B6F-0D81B153C1BB</gtr:id><gtr:name>European Hopital Georges Pompidou</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E0B387A0-6112-403A-A75B-195969D14DF1"><gtr:id>E0B387A0-6112-403A-A75B-195969D14DF1</gtr:id><gtr:firstName>K</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Marchbank</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7A20962B-952E-4629-A6B0-C6CD433A62B8"><gtr:id>7A20962B-952E-4629-A6B0-C6CD433A62B8</gtr:id><gtr:firstName>Tim</gtr:firstName><gtr:surname>Goodship</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701325"><gtr:id>8C8D5EDA-B033-4413-9D92-07612ABBBAF3</gtr:id><gtr:title>Complement susceptibility factors in atypical haemolytic uraemic syndrome, age related macular degeneration and ageing.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701325</gtr:grantReference><gtr:abstractText>Haemolytic uraemic syndrome (HUS) is usually a serious complication of infection with the bacteria E.Coli O157. This organism causes a severe gastrointestinal infection from which recovery is usual. However, 5-10% of patients develop kidney failure. This is secondary to a bacterial toxin which attaches itself to the lining of blood vessels in the kidney causing them to become blocked. Most patients recover but in a few the illness is severe enough to cause death. 

There is a rarer form of HUS , called atypical, which is not associated with E.Coli O157 infection. Atypical HUS (aHUS) has two variants, sporadic and familial. The sporadic form occurs often without any preceding illness but can be associated with use of certain drugs (most notably the oral contraceptive), pregnancy and HIV infection. Recovery of kidney function is less common and many patients require long term dialysis. In the familial form several members of a family will, over a period of time, be affected in a way similar to the sporadic form.

We have found abnormalities in the genes for four proteins, called factor H, membrane cofactor protein, factor I and C3 in approximately 50% of aHUS. These all belong to a common group of proteins, named complement. They have an important role in allowing the body to differentiate between its own and foreign cells. If any of these genes is faulty then the body?s own cells can be damaged by mechanisms designed to destroy foreign cells.

There is evidence that in a small number of patients with aHUS that there are faults in more than one of these genes. We have DNA samples from nearly 250 patients with aHUS and wish to screen all the known genes even in those patients in whom we have already found one fault.

We have recently found that the structure of the chromosome on which these genes lies is in some individuals with aHUS rearranged to form new genes, the presence of which predispose to the disease. We have also found that such rearrangements can lead to loss of genes and that this can predispose to another more common disease called age related macular degeneration. This is the commonest form of blindness in the elderly and has been shown to be associated with the factor H gene. We now wish to determine what the biological effect of loss of these genes is and whether it is more common with increasing age.</gtr:abstractText><gtr:technicalSummary>It is now well established that the complement pathway is associated with both atypical haemolytic uraemic syndrome (aHUS) and age related macular degeneration (AMD). It has been shown that both mutations and susceptibility factors (SNPs and copy number variability) in complement genes including factor H, membrane cofactor protein, factor I, factor B and C3 predispose to aHUS. There is evidence to suggest that multiple such factors in individual patients can act in a summative manner to increase the risk of disease development. In the Newcastle cohort of 246 aHUS patients we will use a systems biology approach to model these multiple factors. Mutation screening, genotyping and dosage analysis will be undertaken to provide a complete profile of all these factors in the entire cohort. We will in the cohort also undertake mutation screening of other potential candidate genes including CD59, CR1 and properdin. We recently showed that a hybrid factor H/factor H related protein 1 gene formed by non-allelic homologous recombination (NAHR) was associated with aHUS. In this application we will confirm the presence of the reverse factor H related protein 1/factor H hybrid gene in association with aHUS using cDNA analysis and southern blotting. We have also shown that NAHR results in deletion of the genes encoding factor H related proteins 1 and 3 (CFHR1 and CFHR3), and that this deletion protects against the development of AMD but predisposes to aHUS. We will examine in normal subjects whether copy number of CFHR1 and CFHR3 is associated with serum levels of the proteins encoded by these genes and serum levels of factor H. To do this we will develop an ELISA for CFHR1 and CFHR3. In our studies examining copy number of CFHR1 and CFHR3 in aHUS and AMD we have observed that in control groups that the allele frequency of the deletion increases with ageing. We will examine the hypothesis that cumulative survival in the general population is associated with this deletion by examining the allele frequency in 4 independent cohorts of normal controls.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>399999</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Universitario La Paz</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>5CB95A3D-2998-4EB4-B823-766B21EC3042</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-5</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biosciences</gtr:department><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>E8138106-AB9D-4CDA-A64A-ADEA1AA5F1B5</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-9</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Hopital Georges Pompidou</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>AA122B57-2ECB-4E62-BF91-F40B85B72F5F</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-1</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mario Negri Institute for Pharmacological Research</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>6A065C9D-C39A-45E0-B5AC-C6527C0156B7</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-2</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>8092DEBC-CB9E-45CE-B776-8114B4B26892</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-8</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>0AABFC2A-8533-49DB-9FD0-666D3333B924</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-6</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>1FAEFF8B-8ED3-4CED-A574-567C84DBFC3B</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-7</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spanish National Research Council (CSIC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>E2154490-0373-4A17-8A00-A4FD4BB1A721</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-4</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Leibniz Institute for Natural Product Research and Infection Biology</gtr:department><gtr:description>The European Working Party on Complement Genetics in Renal Disease</gtr:description><gtr:id>2F11B246-4B52-4408-8D8B-B8877C1F60AE</gtr:id><gtr:impact>With MRC Funding we have so far published one paper (18796626) in the period up to the end of 2008</gtr:impact><gtr:outcomeId>4767FAB792D-3</gtr:outcomeId><gtr:partnerContribution>Undertaking analyses on serum and DNA samplesUndertaking analyses on serum and DNA samples. Sharing data.Undertaking analyses on serum and DNA samples. Sharing dataUndertaking analyses on serum and DNA samples. Sharing data and methods.Undertaking analyses on serum and DNA samples. Sharing data and methodsUndertaking analyses on serum samplesUndertaking analyses on DNA samples. Sharing methodsSharing reagents and methodsUndertaking structural analyses</gtr:partnerContribution><gtr:piContribution>Undertaking analyses on serum and DNA samples. Sharing reagents and methods. Sharing data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>aHUS patient/family conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>4D13C965-9B39-40DB-A0B0-2999940D87EB</gtr:id><gtr:impact>100 individuals attended a series of talks covering all aspects of aHUS. The talks were all recorded and are online at www.ahus.org.uk.

As a consequence of the meeting a patient/family support group (aHUSUK) has been established.</gtr:impact><gtr:outcomeId>SMZYAp6AiGB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.ahus.org.uk</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parliamentary seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9BF5E4D5-04C4-4B2A-B330-CA860C2DED3E</gtr:id><gtr:impact>About 30 people attended including MPs, patients, family members, carers and clinicians. There were also representative from Kidney Research UK, Alexion Pharmaceuticals, Rare Diseases UK, the Department of Health and aHUSUK.

The impact of the disease on patients and their families was well documented by a patient who spoke</gtr:impact><gtr:outcomeId>DwLMbiert2Q</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit - Newcastle upon Tyne</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>693B6D5D-7D04-4C65-8921-EC0F7F228A61</gtr:id><gtr:impact>I gave a lecture on the genetics of haemolytic uraemic syndrome to the Medical Society of the Royal Grammar School, Newcastle upon Tyne.

I received the following e-mail after my lecture. &amp;quot;Dear Professor Goodship, I would like to thank you on behalf of the society for giving the RGS an excellent talk on Genetics and its role in Hemolytic-uremic syndrome. All those I have spoken to found the talk extremely insightful, and I'm sure it will provide a useful talking point for any potential interviews our members have. We hope you enjoyed your time at the RGS and wish you all the best for the future. Yours sincerely, Sami Anjum RGS Medical Society Chairman</gtr:impact><gtr:outcomeId>68F12C98BB3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in the Newcastle Evening Chronicle</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>7D94688B-7B35-4A70-886F-573AD7E58847</gtr:id><gtr:impact>An article in the Evening Chronicle described the experiences of one member of a family from the North East where multiple individuals have been affected by aHUS. I wrote a short accompanying article describing what aHUS was.

Since this article there have been two further articles in the Evening Chronicle describing the experiences of other local individuals affected by aHUS.</gtr:impact><gtr:outcomeId>197E6552486</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>aHUS action</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>2A704F92-B622-44CC-9FD0-C91D2A712F52</gtr:id><gtr:impact>We have established a coalition group called aHUS Action which is campaigning for better NHS care for patients with atypical haemolytic uremic syndrome (aHUS) in England.We are calling for a national specialised service for the diagnosis and treatment of aHUS, and to ensure that new therapies are available to all patients who need them. Details of the group are available at www.ahus-action.org.


An online e-petition &amp;quot;Treatment of atypical haemolytic uraemic syndrome&amp;quot; has been signed by over 1200 individuals. The petition is available at http://epetitions.direct.gov.uk/petitions/16053
An early day motion (http://www.parliament.uk/edm/2010-12/2046) has been signed by 21 MPs.</gtr:impact><gtr:outcomeId>Sde5LE1Vf5K</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.ahus-action.org</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview for BBC Radio York</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>57BC380E-C546-4608-A53D-4FD6432AC080</gtr:id><gtr:impact>I was interviewed for a lunch time programme broadcast on BBC Radio York about atypical haemolytic uraemic syndrome. This was in response to a local patient with the disease who had called the station about how the disease had affected her.

This raised the profile of a rare disease through local media.</gtr:impact><gtr:outcomeId>VUkonLFSSrk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rare Disease Working Groups</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:fundingRef>SP9/RDWG/2011</gtr:fundingRef><gtr:id>72725ED9-1031-43BE-B6B7-A10D692CB118</gtr:id><gtr:outcomeId>dasg84Y82Yd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106851</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>FP7-HEALTH-2012-INNOVATION-1</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>46247668-1186-4E49-B9AC-2D42D8CFEAF1</gtr:id><gtr:outcomeId>UMRJ2ouC6au</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant/Northern Counties Kidney Research Fund</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Northern Counties Kidney Research Fund</gtr:fundingOrg><gtr:id>872BD779-0764-4833-B3FE-3EA07B9593BA</gtr:id><gtr:outcomeId>k5Pak3jNGyy0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56711</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Kids Kidney Research</gtr:fundingOrg><gtr:id>8954AF3B-FAE5-4F48-B158-6513B7EB59F2</gtr:id><gtr:outcomeId>NTqodxPEPpp0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>137741</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>F2734374-028C-4AB7-9D5C-680BA70EF999</gtr:id><gtr:outcomeId>QzTrjjAPU130</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>aHUS UK Guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom (Pubmed 19821824)</gtr:guidelineTitle><gtr:id>C11EE0FE-05C3-45CD-933E-E1B8469BDDA3</gtr:id><gtr:outcomeId>8B7C977A67C</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19821824</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National service for aHUS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>97406CBE-AF40-41C3-B0D8-621BEDC45CC5</gtr:id><gtr:impact>We applied for a national commissioned service for the treatment and investigation of aHUS. This was considered by the Advisory Group for National Specialised Services (AGNSS). Subsequently the Department of Health asked NICE to undertake a review. This recommended funding of eculizumab by NHS England. We in 2016 (Newcastle upon Tyne Hospitals NHS Foundation Trust) then successfully applied to NHS England to provide the national specialist service for aHUS.</gtr:impact><gtr:outcomeId>qq7ny9tFtLN</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NHS England Clinical Commissioning Policy Statment: Eculizumab for atypical HUS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4D73FC69-2BC6-4FB4-AA23-0ECF324E8DAD</gtr:id><gtr:impact>Based on the results of the trials on eculizumab for which I was the UK chief investigator NHS England have funded eculizumab for the treatment of new aHUS patients and for those aHUS patients on dialysis who are suitable for transplantation.</gtr:impact><gtr:outcomeId>ctoViBRjRrN</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have participated in a multicentre study examining the use of eculizumab, a monoclonal anti-C5 antibody, in aHUS. The results of the study have resulted in licences being granted for the use of eculizumab in aHUS by the FDA and EMA.</gtr:description><gtr:id>96E16EFC-1AED-44B0-BFBC-AD9DA01A913C</gtr:id><gtr:impact>The results of the study have been extremely encouraging and are likely to have a dramatic effect on the poor prognosis associated with aHUS.</gtr:impact><gtr:outcomeId>AqntwcoFibW</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Use of eculizumab in aHUS</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have refined the use of multiplex ligation-dependent probe amplification (MLPA) for the diagnosis of genomic disorders affecting the RCA cluster at 1q32</gtr:description><gtr:id>ED90584F-080B-4F5C-8EDE-0BC3EF08027E</gtr:id><gtr:impact>We have recently published a paper in Blood (Pubmed 19861685) which describes a novel deletion identified using MLPA</gtr:impact><gtr:outcomeId>C2749DAF670</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Use of MLPA for idenfity genomic disorders in the RCA cluster at 1q32</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19861685</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>87FD1784-7996-43FC-8BF1-66793B3BA171</gtr:id><gtr:title>Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9637de6eabefa2d20922ed9f3dc0833"><gtr:id>f9637de6eabefa2d20922ed9f3dc0833</gtr:id><gtr:otherNames>Noris M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>Jf3adutbbvz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18BCCB73-3715-49CF-B05A-776258FBED97</gtr:id><gtr:title>Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e871953f5867c490b812de6ac834bf4"><gtr:id>3e871953f5867c490b812de6ac834bf4</gtr:id><gtr:otherNames>Bresin E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_12511_21_23431077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33DA05AC-9BB3-4534-A159-C5C69025F448</gtr:id><gtr:title>Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome-A pedigree revisited.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d103efcc57a8cfd120843248736168"><gtr:id>a5d103efcc57a8cfd120843248736168</gtr:id><gtr:otherNames>Johnson SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>SN442Qf29QJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>779A545B-B592-4502-ACB4-8F01E2E57367</gtr:id><gtr:title>Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ed8c05a2eb8a6b16f7af589920e6999"><gtr:id>0ed8c05a2eb8a6b16f7af589920e6999</gtr:id><gtr:otherNames>Moore I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>AAA68F01A36</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8038CA10-0E16-411A-9F5B-5FB57055258F</gtr:id><gtr:title>Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/496c6f8776d1651525ea524984415a40"><gtr:id>496c6f8776d1651525ea524984415a40</gtr:id><gtr:otherNames>Waters AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>00D57B65CE8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB1B60DB-DCD6-46D5-828B-AF345C24C89A</gtr:id><gtr:title>Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11e74e5a3a7b3794a49aa81194f3c27f"><gtr:id>11e74e5a3a7b3794a49aa81194f3c27f</gtr:id><gtr:otherNames>Zhao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>A96B858A_CA96B858A_C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3C613BF-82AE-495D-9FEB-EB73587FE3D5</gtr:id><gtr:title>Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H.</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c690504953331fb806cb15021dc1c29b"><gtr:id>c690504953331fb806cb15021dc1c29b</gtr:id><gtr:otherNames>Wilson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>doi_55faa1aa1d5a1458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F4383F5-184D-448D-AFAD-9DABA599A14A</gtr:id><gtr:title>Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ad81811cead7fc395938bf1797e0921"><gtr:id>9ad81811cead7fc395938bf1797e0921</gtr:id><gtr:otherNames>Ermini L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>pm_12511_21_22153652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBF70AE8-0CC6-4C49-9294-CEBCF8C45610</gtr:id><gtr:title>Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34319332a088bfc8fdba6aaccb8dc1f1"><gtr:id>34319332a088bfc8fdba6aaccb8dc1f1</gtr:id><gtr:otherNames>Holmes LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12511_21_23613724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20DDC155-D90C-4E16-9C02-1A497E7871D9</gtr:id><gtr:title>Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3677fff7e8e7835c6a6b4e5b2c903158"><gtr:id>3677fff7e8e7835c6a6b4e5b2c903158</gtr:id><gtr:otherNames>Brown JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_12511_21_22420623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B5FC666-1A58-4301-8D27-C387F4E0BCA0</gtr:id><gtr:title>Factors determining penetrance in familial atypical haemolytic uraemic syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3e3f5fb295f8e0ce7af9bae4b10868c"><gtr:id>c3e3f5fb295f8e0ce7af9bae4b10868c</gtr:id><gtr:otherNames>Sansbury FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>5451027f2598e3.28929609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>905042FB-BCB4-41E0-ADB1-5EA3CDDA834D</gtr:id><gtr:title>Complement factor h autoantibodies and age-related macular degeneration.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/997fac510f4db4c753fc4e05f129ad0e"><gtr:id>997fac510f4db4c753fc4e05f129ad0e</gtr:id><gtr:otherNames>Dhillon B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>EtBiungQimT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F36251DC-3F33-4226-BFDF-102EB18D3D9C</gtr:id><gtr:title>A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e14fdc471a7f645ab7c2d9aeab31012"><gtr:id>3e14fdc471a7f645ab7c2d9aeab31012</gtr:id><gtr:otherNames>Challis RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>585d670c387416.28658633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6767CEE-FF7A-43A3-9E06-2E9ADA2BC9EA</gtr:id><gtr:title>Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a28f2f545ecea8c08c615f27af64f94c"><gtr:id>a28f2f545ecea8c08c615f27af64f94c</gtr:id><gtr:otherNames>Kavanagh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>pm_12511_21_22223611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>191D98A4-CA6D-493B-85F8-200AD2F66587</gtr:id><gtr:title>A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be7f3be6b4153213b48fba9ec2faa3b7"><gtr:id>be7f3be6b4153213b48fba9ec2faa3b7</gtr:id><gtr:otherNames>Francis NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>btn7UvxappS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA2D5975-49BC-4238-AF3D-4A155CE2C32A</gtr:id><gtr:title>Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c4999bd2283ce8faae2b5afe6e1975c"><gtr:id>1c4999bd2283ce8faae2b5afe6e1975c</gtr:id><gtr:otherNames>Fr?meaux-Bacchi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>F6730A5719F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03BE5CF5-B8CD-4687-BF92-1F5E4F3C1986</gtr:id><gtr:title>Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e3cd49a666758b9e2d817bb5c6e60c0"><gtr:id>5e3cd49a666758b9e2d817bb5c6e60c0</gtr:id><gtr:otherNames>Schramm EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5675ded5c608f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>689CCC7C-F164-4503-A4CA-AFEBE917D8BC</gtr:id><gtr:title>Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f752ec2537b73aefe75bfa21025d4021"><gtr:id>f752ec2537b73aefe75bfa21025d4021</gtr:id><gtr:otherNames>Salmon JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>F0265FA1_0F0265FA1_0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEEC880A-D24B-4CEC-B20A-3F498E024892</gtr:id><gtr:title>Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1).</gtr:title><gtr:parentPublicationTitle>Renal failure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ca6eb015673007b72473f66535cbad1"><gtr:id>1ca6eb015673007b72473f66535cbad1</gtr:id><gtr:otherNames>Bento D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0886-022X</gtr:issn><gtr:outcomeId>m1fqG88p6jk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F705A0D4-0FBD-4FFB-9884-D437B2FF3D6C</gtr:id><gtr:title>Genotype/phenotype correlations in complement factor H deficiency arising from uniparental isodisomy.</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf2f978417b371700309d0ce0b9078e0"><gtr:id>cf2f978417b371700309d0ce0b9078e0</gtr:id><gtr:otherNames>Wilson V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>pm_12511_21_23870792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA48A0DA-C992-49CB-AF03-CABD7EA97D45</gtr:id><gtr:title>Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d75c0bcc9053e9a07e2905e563de2ba8"><gtr:id>d75c0bcc9053e9a07e2905e563de2ba8</gtr:id><gtr:otherNames>Kim JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>q5Ez167DW82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AEE8C50-C0DF-4F76-B348-29D6DC7ED320</gtr:id><gtr:title>Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16642dafb9bee43e70c6c84c9550c10c"><gtr:id>16642dafb9bee43e70c6c84c9550c10c</gtr:id><gtr:otherNames>Haller W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>AoSbTBJVK3D</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701325</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>